SCHEMBL9963002

SCHEMBL9963002

COC(=O)c1ccc(C#CCC[C@@H](N)[C@H](C)c2ccc(Cl)nc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.40
CHRNA4 P43681 1/20 0.40
POLB P06746 1/20 0.36
PKM P14618 1/20 0.36
DPP4 P27487 2/20 0.36
ACACB O00763 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
MAPT P10636 1/20 0.34
PTPN11 Q06124 1/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
CYP2C19 P33261 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9963001 0.90 CHRNB2 (0.41) CHRNB2CHRNA4POLBPKMACACB
SCHEMBL18017384 0.86 NPC1 (0.39) DPP4ACACBMAPTPTPN11KDM4E
SCHEMBL18017407 0.85 MAPT (0.34) POLBDPP4ACACBMAPTPTPN11
SCHEMBL9933447 0.84 CHRNB2 (0.35) CHRNB2CHRNA4POLBPKMDPP4
SCHEMBL18017397 0.79 ADORA2B (0.38) DPP4MAPTPTPN11KDM4EALDH1A1
SCHEMBL16619389 0.74 NPC1 (0.34) DPP4PTPN11KDM4EALDH1A1CYP1A2
SCHEMBL21278205 0.74 NPC1 (0.34) DPP4PTPN11KDM4EALDH1A1CYP1A2
SCHEMBL21278568 0.73 MMP13 (0.31) MAPTLMNAGAAALDH1A1MMP13
SCHEMBL403166 0.72 FFAR1 (0.47) CHRNB2CHRNA4SMN1; SMN2MAPTPTPN11
SCHEMBL21278410 0.68 ADORA2B (0.35) DPP4PTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120225886-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-09-06 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225886-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 CHRNB2 43/4885CHRNA4 48/4885POLB 1198/4885
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 CHRNB2 43/4885CHRNA4 48/4885POLB 1198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.